EVALUATION OF THE EFFICACY AND SAFETY OF THE ART REGIMENS CONTAINING LOW DOSES PHOSPHAZID
In 20 patients, treated with regime of ART including phosphazid at a dose of 800 mg/day, his daily dose was reduced to 400 mg. In 19 of 20 patients the phosphazod’ dose reduction was due to the development of adverse events related to therapy. After changing the phosphazid’ daily dose the patients s...
Saved in:
| Main Authors: | N. V. Sizova, I. O. Modestova, F. F. Shakhova, N. V. Koplevskaya, O. A. Klitsenko, A. V. Kravchenko, O. G. Yurin, D. A. Gusev |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Journal Infectology
2017-10-01
|
| Series: | Журнал инфектологии |
| Subjects: | |
| Online Access: | https://journal.niidi.ru/jofin/article/view/634 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Сасо-2 INTESTINAL PERMEABILITY AND Pgp-AFFINITY OF PHOSPHAZIDE
by: D. Yu. Grebenkin, et al.
Published: (2019-01-01) -
DEVELOPMENT AND REGISTRATION OF A COMBINED DRUG FOR THE TREATMENT OF HIV INFECTION ON THE BASIS OF ON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI) PHOSPHAZIDE AND LAMIVUDINE
by: A. F. Khohlov, et al.
Published: (2019-01-01) -
Comparison of efficacy and safety of antiretroviral first-line therapy with phosphazideortdf
by: A. V. Kravchenko, et al.
Published: (2018-12-01) -
DISSOLUTION PROFILE STUDY FOR INNOVATION ANTI-RETROVIRAL DRUG PRODUCT NIKAVIR® AND ITS FIXED COMBINATION WITH LAMIVUDINE (PHOSPHALADINE®)
by: I. E. Shohin, et al.
Published: (2019-01-01) -
Sex differences in adenosine deaminase activity associate with disparities in SARS-CoV-2 innate immunity
by: Priyanka Saminathan, et al.
Published: (2025-05-01)